drugset / Trial / NCT01133665
Cetuximab and Lenalidomide in Head and Neck
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to study specific FcRIIIa polymorphisms and their correlation with clinical outcome in subjects treated with cetuximab and lenalidomide.
Timeline
- Start
- 2010-02
- Primary completion
- 2011-08
- Completion
- 2012-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | — | — |
| Subject | Lenalidomide | Other / unclassified | — | — |